Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Bought by CreativeOne Wealth LLC

CreativeOne Wealth LLC raised its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 10.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,167 shares of the medical equipment provider’s stock after acquiring an additional 499 shares during the quarter. CreativeOne Wealth LLC’s holdings in Lantheus were worth $567,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its stake in Lantheus by 184.1% in the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock valued at $26,000 after purchasing an additional 208 shares during the last quarter. Signaturefd LLC grew its holdings in shares of Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after buying an additional 92 shares in the last quarter. Nkcfo LLC acquired a new stake in shares of Lantheus in the second quarter valued at about $47,000. UMB Bank n.a. lifted its stake in shares of Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new position in Lantheus during the third quarter worth about $51,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

LNTH has been the subject of a number of recent research reports. Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. JMP Securities cut their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a report on Thursday, November 7th. StockNews.com lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, Redburn Atlantic began coverage on Lantheus in a report on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 target price for the company. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, Lantheus has a consensus rating of “Moderate Buy” and a consensus target price of $125.71.

Lantheus Stock Down 1.1 %

Shares of Lantheus stock opened at $89.27 on Friday. The business’s fifty day simple moving average is $101.34 and its 200-day simple moving average is $97.12. The firm has a market cap of $6.21 billion, a PE ratio of 14.85 and a beta of 0.51. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.